6,840 Shares of iRadimed Corporation $IRMD Purchased by Kings Path Partners LLC

Kings Path Partners LLC purchased a new stake in iRadimed Corporation (NASDAQ:IRMD) during the third quarter, HoldingsChannel reports. The institutional investor purchased 6,840 shares of the medical equipment provider’s stock, valued at approximately $590,000.

A number of other institutional investors also recently modified their holdings of the company. Nisa Investment Advisors LLC grew its holdings in shares of iRadimed by 49.6% during the third quarter. Nisa Investment Advisors LLC now owns 1,643 shares of the medical equipment provider’s stock worth $142,000 after buying an additional 545 shares in the last quarter. IFP Advisors Inc lifted its stake in iRadimed by 308.4% in the 3rd quarter. IFP Advisors Inc now owns 2,324 shares of the medical equipment provider’s stock valued at $200,000 after acquiring an additional 1,755 shares in the last quarter. Davidson Capital Management Inc. lifted its stake in iRadimed by 11.2% in the 3rd quarter. Davidson Capital Management Inc. now owns 63,017 shares of the medical equipment provider’s stock valued at $5,433,000 after acquiring an additional 6,333 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in iRadimed during the 2nd quarter worth approximately $28,000. Finally, NewEdge Advisors LLC boosted its position in iRadimed by 46.9% during the 2nd quarter. NewEdge Advisors LLC now owns 25,254 shares of the medical equipment provider’s stock worth $2,413,000 after acquiring an additional 8,063 shares during the last quarter. 92.34% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on IRMD. Weiss Ratings raised shares of iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 16th. Wall Street Zen downgraded shares of iRadimed from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Needham & Company LLC started coverage on shares of iRadimed in a research report on Tuesday, September 22nd. They issued a “hold” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, iRadimed currently has an average rating of “Moderate Buy” and an average price target of $120.00.

Insider Buying and Selling

In related news, Director Monty K. Allen sold 1,419 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total transaction of $122,615.79. Following the completion of the transaction, the director directly owned 19,581 shares of the company’s stock, valued at approximately $1,691,994.21. This represents a 6.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 34.60% of the company’s stock.

iRadimed Price Performance

Shares of NASDAQ:IRMD opened at $87.81 on Thursday. The company’s 50-day moving average price is $86.03 and its two-hundred day moving average price is $90.19. iRadimed Corporation has a one year low of $75.58 and a one year high of $107.90. The stock has a market capitalization of $1.12 billion, a PE ratio of 49.30 and a beta of 0.91.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. The company had revenue of $20.47 million during the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts anticipate that iRadimed Corporation will post 1.98 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 28th. Investors of record on Friday, August 14th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s dividend payout ratio is 44.69%.

About iRadimed

iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.